A Single-Center Phase I Dose Escalation/Response Trial to Evaluate Safety, Tolerability, and Anti-Tumor Efficacy of Intra-Arterial CBL0137 for Patients With Advanced Extremity Melanoma or Sarcoma
Latest Information Update: 29 Mar 2024
At a glance
- Drugs CBLC 137 (Primary)
- Indications Malignant melanoma; Sarcoma
- Focus Adverse reactions
- 25 Mar 2024 Status changed from recruiting to discontinued due to low enrollment.
- 22 Jul 2021 Planned End Date changed from 8 Aug 2022 to 8 Aug 2024.
- 22 Jul 2021 Planned primary completion date changed from 8 Aug 2021 to 8 Aug 2024.